Nausea And Vomiting Treatment Companies – Top 13 Company List [Updated] | Global Growth Insights

Nausea and vomiting (N&V) are common symptoms associated with various conditions such as chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), morning sickness, and motion sickness. The rising prevalence of cancer, gastrointestinal disorders, and post-surgical complications is driving the demand for effective treatment options.

According to the World Health Organization (WHO), nearly 70% of cancer patients undergoing chemotherapy experience nausea and vomiting. In addition, 30% of patients experience PONV after surgery, highlighting the significant demand for antiemetic medications worldwide. The global market for nausea and vomiting treatments is growing steadily, driven by increased awareness, advancements in drug formulations, and the availability of over-the-counter (OTC) medications.

Nausea And Vomiting Treatment Market size was valued at USD 6.33 billion in 2023 and is anticipated to grow to USD 6.86 billion in 2024, reaching approximately USD 13.0 billion by 2032. This represents a compound annual growth rate (CAGR) of 8.34% during the forecast period from 2024 to 2032.

USA: Growing Nausea and Vomiting Treatment Market

The United States holds a dominant share in the nausea and vomiting treatment market due to high cancer prevalence, advanced healthcare infrastructure, and increasing drug approvals. In the U.S., nearly 1.9 million new cancer cases were diagnosed in 2022, according to the American Cancer Society, leading to a growing demand for chemotherapy-induced nausea and vomiting (CINV) treatments.

Post-operative nausea and vomiting (PONV) affect approximately 30%–50% of surgical patients in the U.S., with female patients at a higher risk (60%-80%) compared to males. The increasing number of surgeries, coupled with the rise in gastrointestinal disorders, has contributed to a 15% increase in demand for antiemetic medications in the last five years.

Over-the-counter (OTC) medications for nausea and vomiting have also seen substantial growth, with brands such as Dramamine and Pepto-Bismol reporting a 12% increase in sales in 2022 due to rising consumer awareness and self-medication trends.

Global Growth Insights unveils the top global Nausea And Vomiting Treatment Companies:

1. Qilu Pharma

• Headquarters: Jinan, China
• Revenue (2022): $4.6 billion
• A major pharmaceutical firm specializing in oncology-related treatments. Its anti-nausea drug sales grew 12% in China, driven by rising chemotherapy-induced nausea cases. Revenue (2022): $4.6 billion.

2. Taiji Group

• Headquarters: Chongqing, China
• Revenue (2022): $1.7 billion
• Leading producer of traditional Chinese and modern medicines. It saw a 9% growth in antiemetic sales, attributed to increasing gastroenteritis cases. Revenue (2022): $1.7 billion.

3. Teva Pharmaceutical Industries Ltd.

• Headquarters: Petah Tikva, Israel
• Revenue (2022): $15.9 billion
• A global pharmaceutical giant with a 15% expansion in its anti-nausea portfolio, primarily in North America and Europe. Revenue (2022): $15.9 billion.

4. Sanofi

• Headquarters: Paris, France
• Revenue (2022): $43 billion
• Market Share Contribution: 10%
• A major player in OTC and prescription anti-nausea medications. Sales surged 14%, driven by increased consumer demand in Europe. Revenue (2022): $43 billion.

5. Novartis

• Headquarters: Basel, Switzerland
• Revenue (2022): $51.6 billion
• Market Share Contribution: 12%
• A leading provider of oncology-related nausea treatments. Demand for its antiemetics grew 20%, especially in the U.S. and Europe. Revenue (2022): $51.6 billion.

6. Merck & Co. Inc.

• Headquarters: Kenilworth, New Jersey, USA
• Revenue (2022): $59.3 billion
• Market Share Contribution: 13%
• Invested heavily in R&D, driving a 17% rise in anti-nausea drug sales, particularly in cancer therapy. Revenue (2022): $59.3 billion.

7. Heron Therapeutics

• Headquarters: San Diego, California, USA
• Revenue (2022): $105 million
• Market Share Contribution: 2%
• Specializes in post-operative nausea and vomiting (PONV) treatments. Its sales rose 11% in 2022. Revenue (2022): $105 million.

8. Tesaro (GSK Company) (Waltham, USA)  – Focuses on oncology and nausea treatments, with a 10% increase in demand for its CINV drugs. Revenue (2022): $1.1 billion.
9. Duchesnay (Blainville, Canada) – Known for pregnancy-related nausea treatments; experienced a 9% growth in demand for its flagship products. Revenue (2022): $312 million.
10. Kyowa Kirin (Tokyo, Japan) –biotech company with a 13% growth in nausea-related therapies, especially in Asia. Revenue (2022): $3.9 billion.
11. Atnahs Pharma UK (Basildon, UK) – Specializes in niche pharmaceuticals, with a 7% increase in demand for anti-nausea products. Revenue (2022): $272 million.
12. Unimed Pharmaceuticals (AbbVie Inc.) (North Chicago, USA)– A key player in nausea treatments, contributing to AbbVie's $58 billion revenue, with 8% growth in the segment.
13. Mylan (Canonsburg, USA) – Offers a broad portfolio of generic anti-nausea drugs, seeing an 11% rise in demand. Revenue (2022): $11 billion.

Regional Market Share and Opportunities in Nausea and Vomiting Treatment

North America (Market Share: 40%)

North America holds the largest market share of around 40%, driven by strong research and development (R&D) investments and the increasing approval of novel antiemetic drugs. The U.S. Food and Drug Administration (FDA) approved multiple anti-nausea medications in recent years, including Aprepitant and Rolapitant, which have improved efficacy for chemotherapy-induced nausea and vomiting (CINV).

The North American market is projected to expand by 10% in drug adoption, particularly for newer treatments that address treatment-resistant nausea and vomiting.

Europe (Market Share: 25%)

Europe follows closely with a market share of 25%, driven by a growing geriatric population and the increasing prevalence of motion sickness and post-surgical nausea cases. In Germany, France, and the UK, nearly 35% of surgeries lead to PONV cases, increasing the demand for ondansetron and metoclopramide.

Asia-Pacific (Market Share: 20%)

The Asia-Pacific region accounts for approximately 20% of the global market, with China and Japan leading due to the rising incidence of cancer. According to the China National Cancer Center, nearly 4.57 million new cancer cases were reported in 2022, with CINV cases increasing by 18% over the last decade.

The availability of cost-effective antiemetic drugs in India and China has led to a 14% increase in the adoption of generic medications. Additionally, growing medical tourism in Southeast Asia has boosted demand for PONV treatment.

Latin America & Middle East (Market Share: 15%)

Latin America and the Middle East collectively contribute to about 15% of the global market, driven by the increasing adoption of antiemetic drugs in oncology and gastroenterology. Countries like Brazil, Mexico, and the UAE have seen a 20% rise in anti-nausea drug prescriptions due to improved access to healthcare facilities and rising disposable income.

Conclusion: What’s Next for the Nausea and Vomiting Treatment Market?

The nausea and vomiting treatment market is experiencing steady growth, fueled by rising cancer cases, an increasing number of surgeries, and lifestyle-related gastrointestinal issues. The demand for CINV, PONV, and motion sickness treatments has grown by 10%-15% annually, with key pharmaceutical players expanding their portfolios.

• North America remains the leader in the global market, with a share of ~40%.
• Europe follows with ~25%, driven by healthcare advancements.
• Asia-Pacific is growing rapidly, with a 20% market share and increasing adoption of generic antiemetics.
• Latin America and the Middle East are emerging markets, contributing ~15% to global sales.

With continuous innovations in drug formulations and increasing approvals for novel treatments, the global nausea and vomiting treatment market is expected to see robust growth in the coming years.